Donanemab is an immunoglobulin gamma 1 (IgG1) monoclonal antibody with high affinity for a modified, N-terminal truncated form of amyloid beta (N3pE Aβ). N3pE Aβ is present in brain amyloid plaques at low levels, and not detected in plasma and CSF. Donanemab binds to N3pE Aβ and aids plaque removal through microglial-mediated phagocytosis.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| N06DX05 | N Nervous system → N06 Psychoanaleptics → N06D Anti-dementia drugs → N06DX Other anti-dementia drugs | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| KISUNLA Concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| KISUNLA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Donanemab is an active ingredient of these brands:
Austria (AT)Lithuania (LT)Romania (RO)United States (US)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.